Novo Nordisk has found the formula to recover the profitability of Ozempic: fire 9,000 employees
The Pharmaceutical Novo Nordisk, manufacturer of Ozempic and Wegovy, is living one of the biggest turbulence in its history recent. After losing the favor of investors and a good part of its stock market value in the last year, the company has announced a drastic reduction of workforce that affects 9,000 employees around the world: 11.5% of the total staff. 9,000 layoffs, most in Denmark. Novo Nordisk has confirmed Through a statement the cut of 9,000 jobs in the coming years, a figure that represents 11.5% of its template globally, composed of 78,400 employees. Denmark, a country of origin of the pharmaceutical, will be the country that will receive the greatest impact of that measure, accumulating about 5,000 of the planned dismissals. The firm has not yet specified how layoffs will be distributed in the rest of international venues, since the decision is subject to “to the relevant consultations in accordance with local labor legislation.” The multinational has remarked that “this is a global transformation, and each country, headquarters or region will be affected differently,” underlining the international dimension of its labor adjustment process. Multimillionaire savings and business reorganization. With this cut, the pharmaceutical enhance business lines centered on the Research for new treatments For diabetes and obesity, putting greater emphasis on commercial initiatives. It should be remembered that, in origin, both Ozempic and Wegovy were born as a new treatment to enhance insulin generation, but its satiating effects turned out to be much more profitable. Among the objectives mentioned in the official statement include organizational simplification, the increase in speed in decision making and the reallocation of resources towards the strategic fields of the company. According to the statement, Nordisk “must evolve in a market that has become more competitive and consumer oriented”, which implies “a change of mentality and approach that allows us to be faster and faster.” According to published by Reutersthe company would have asked its employees to return to its full -time offices within that same restructuring and optimization plan for its operations. Bursatile bleeding as a trigger. The collapse of the stock market suffered by Novo Nordisk during the last year is the main trigger for the adjustment measure. As published the BBCthe price of your shares was reduced by 60% Since June 2024, losing 430,000 million in stock market capitalization. The situation was especially aggravated on July 30, with a decrease in 23% in a single day After the downward review Growth forecasts and the announcement of the relay in the executive direction. The official presentation of Mike Doustdar as the new CEO of the company has marked the beginning of this stage of changes, which aims to recover the confidence of investors and redefine the corporate culture of the company. Its first measure has had a positive impact on the markets, and after the announcement of the template cuts the value of its shares has increased by 3%. In Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it Image | Flickr (News Oresund, Chemist4u)
